3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
9
Esophageal Squamous Cell Carcinoma
5
Neoplasm Metastasis
4
Carcinoma, Hepatocellular
4
Advanced Solid Tumors
4
Recurrence
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Solid Tumors
1
Sarcoma
1
Neuroendocrine Tumors
1
Nasopharyngeal Neoplasms
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Locally Advanced or Metastatic Urothelial Bladder Cancer
1
Interventions
Rituximab
4
blinatumomab
3
Whole-Body Irradiation
3
Cyclophosphamide
3
fludarabine phosphate
2
Mycophenolic Acid
2
Melphalan
2
Lenalidomide
2
Clofarabine
2
treosulfan
1
thymoglobulin
1
sabatolimab
1
pembrolizumab
1
peginterferon alfa-2a
1
obinutuzumab
1
midostaurin
1
ixazomib
1
fludarabine
1
eribulin
1
daratumumab
1
acalabrutinib
1
Trastuzumab
1
Tacrolimus
1
Sodium Chloride
1
Sirolimus
1
Peripheral Blood Stem Cell Transplantation
1
Pentostatin
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Methotrexate
1
Magnetic Resonance Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Neoplasm, Residual
×
tislelizumab
×
Clear all
No trials found.